Myung in Pharm Co., Ltd.

Myung in Pharm Co., Ltd.

KKRX:317450
42,100.00
KRW
-100.00
(-0.24%)
6,432.21EPS
6.46P/E
606.63BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
14,332.22
- -
- -
23,697.05
21,212.67
Basic EPS, GAAP
- -
- -
- -
3,933.84
- -
6,718
6,432.21
Free Cash Flow per Basic Share
- -
- -
- -
4,181.16
- -
3,853.67
2,149.63
Dividend per Share
- -
- -
- -
- -
- -
923.94
- -
Book Value per Share
- -
- -
25,759.72
- -
- -
54,409.46
55,915.44
Tangible Book Value per Share
- -
- -
25,710.98
- -
- -
54,031.38
55,492.46
Basic Weighted Avg Shares
15
15
15
15
3
12
14
Sales/Revenue/Turnover
- -
- -
209,250
- -
- -
287,254
293,031
Operating Margin (%)
- -
- -
- -
- -
- -
32.2
33.55
Depreciation Expense
- -
- -
- -
- -
- -
10,940
10,160
Net Income, GAAP
- -
- -
- -
57,434
- -
81,435
88,854
Effective Tax Rate (%)
- -
- -
- -
- -
- -
20.26
21.19
Profit Margin (%)
- -
- -
- -
- -
- -
28.35
30.32
Working Capital
- -
138,119
- -
- -
- -
597,125
570,201
LT Debt
- -
- -
- -
- -
1,172
211
299
Total Equity
- -
- -
376,092
- -
- -
794,378
816,365
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,175
959
684
LT Borrowings
- -
- -
- -
LT Finance Leases
211
332
299
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
1,005,940
782,560
606,630

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
643,309
656,624
620,216
Cash, Cash Equivalents & STI
509,692
522,098
470,002
Accounts Receivable, Net
63,651
63,279
64,658
Inventories
64,108
63,019
78,005
Total Current Liabilities
46,184
74,214
50,015
Payables & Accruals
- -
- -
- -
ST Debt
1,175
959
684
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
70,008
68,145
- -
2025
70,255
72,210
72,697
72,092
287,254
2026
72,136
76,106
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
2,168
1,249.67
- -
2025
1,664
1,875
1,619
1,592.66
6,718
2026
1,556.91
1,666
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
923.94
2026
- -
- -
- -
- -
- -

Company Description

CEO
Hang-Myung Lee
Full Time Employees
532
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Hwaseong-si South Korea
IPO Date
Oct 1, 2025
Business
Myung In Pharm Co., Ltd. engages in the research, development, manufacturing, and commercialization of ethical pharmaceuticals, over-the-counter medications, active pharmaceutical ingredients, and specialized formulation products in South Korea and internationally. Founded in 1985 and headquartered in Seoul, South Korea, with major manufacturing and research facilities located in Hwaseong-si, Gyeonggi-do, the company operates as a market leader in central nervous system therapeutics while serving hospitals, clinics, pharmacies, and wholesale distributors. The company's primary business activities are structured around prescription pharmaceuticals, consumer health products, chemical synthesis, and contract manufacturing. Its ethical drug portfolio specializes in central nervous system (CNS) treatments, including antipsychotics such as Rispen, Neurozapin, Lepizol, and Q-Rokel for schizophrenia and bipolar disorders; antidepressants and mood stabilizers such as Newpram and Fluctin; anticonvulsants such as Q-Pam for epilepsy; and cognitive and neurodegenerative therapies such as Silvercept for dementia and Alzheimer's disease, alongside specialized medications for Parkinson's disease, insomnia, and attention deficit hyperactivity disorder. Beyond CNS treatments, the company manufactures cardiovascular agents, including antihypertensive, antithrombotic, antiplatelet, and antianginal formulations; gastrointestinal medications; anti-inflammatory and analgesic drugs; and respiratory agents. Its over-the-counter (OTC) division produces consumer health brands, notably Igatan for periodontal gum care and Mayqueen Q for constipation relief. In addition, the company operates an integrated active pharmaceutical ingredient (API) synthesis division that develops and manufactures high-purity chemical substances for internal formulation and commercial supply, as well as contract development and manufacturing organization (CDMO) services specializing in advanced pellet formulations. In recent developments, Myung In Pharm completed its initial public offering and listed its common shares on the Korea Exchange under ticker 317450 to accelerate international expansion and strengthen corporate governance. The company broadened its advanced neuropsychiatry pipeline by securing an exclusive license, development, and commercialization agreement with Italy-based Newron Pharmaceuticals for evenamide, an orally administered new chemical entity for schizophrenia, and joined the international Phase III ENIGMA-TRS clinical program following regulatory approval in South Korea. Furthermore, the company expanded its neurological pipeline through the in-licensing of Paxroyah (P2B001) for Parkinson's disease and constructed dedicated large-scale pellet production facilities at its Baran manufacturing campus in Hwaseong to scale its CDMO business while pursuing global regulatory certifications across major international markets.